St. Jude Medical (STJ) 73.55 $STJ
St. Jude Medical's Q1 mixed
at Investor's Business Daily - 1 hr 27 mins ago
The maker of medical products reported EPS of 91 cents, up 6% from the year-earlier quarter and in line with analysts' consensus. Revenue fell 1% to $1.345 bil, but that was slightly above views. St. Jude Medical (STJ) forecast Q2 EPS toward the high...
STJ: 73.55 (+4.43)
St. Jude Medical's (STJ) CEO Daniel J. Starks on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 22, 2:15PM CDT
STJ: 73.55 (+4.43)
St. Jude Medical (STJ) Hits 52-Week High on Earnings Beat
at The Street - Wed Apr 22, 1:14PM CDT
Shares of St. Jude Medical (STJ) hit a one-year high of $73.74 on Wednesday after the medical technology developer reported first-quarter earnings that edged analysts' expectations.
STJ: 73.55 (+4.43)
ST JUDE MEDICAL INC (STJ) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Wed Apr 22, 1:08PM CDT
The following ST JUDE MEDICAL INC (STJ) conference call took place on April 22, 2015, 08:00 AM ET. This is a transcript of that earnings call:
STJ: 73.55 (+4.43)
Jim Cramer Sees St. Jude Medical 'Leapfrogging' Competition
at The Street - Wed Apr 22, 10:42AM CDT
TheStreet's Jim Cramer says shares of St. Jude Medical are not done going higher.
STJ: 73.55 (+4.43), XLV: 74.35 (+0.12)
North American Nerve Repair & Regeneration Market by Type, by Procedure - Forecast to 2019
M2 - Wed Apr 22, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs9468/north_american) has announced the addition of the "North American Nerve Repair & Regeneration Market by Type (Neurostimulation, Nerve Conduits, Nerve Protectors, Nerve Wraps, Nerve Connectors), by Procedure (Direct Nerve Repair, Nerve Grafting, Neuromodulation Surgery, Stem Cell Therapy) -Forecast to 2019" report to their offering. The North American nerve repair and regeneration market was valued at $1,671.4 million in 2014. It is projected to reach $2,873.0 million by 2019, at a CAGR of 11.4% during the forecast period. The market, by type, is segmented into nerve repair by neurostimulation (held largest share in 2014) and nerve repair by biomaterials. In North America, the U.S. is a key region the for nerve repair and regeneration market. Nerve repair and regeneration deals with healing damaged nerves and restoring any functioning of body parts lost due to nerve damage. This is one of the more challenging of neurological procedures. The growth of nerve repair and regeneration market has been rapid in all countries, mainly due to the constantly rising surgeries pertaining to nerves and the high incidence of chronic neurological disorders like epilepsy, Parkinson's, and Alzheimer's diseases. The increase in neurological surgeries drives the need for products such as nerve conduits, wraps, protectors, and connectors; thus, it is a driver of market growth. The North American nerve repair and regeneration market constitutes 32.8% of the global nerve repair and regeneration. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Nerve Repair and Regeneration Market, By Product 6 Nerve Repair and Regeneration Market, By Country 7 Nerve Repair and Regeneration Market: Competitive Landscape 8 Nerve Repair and Regeneration Market: Company Profiles - Axogen, Inc. - Integra Lifesciences Corporation - Medtronic, Plc. - Polyganics - St. Jude Medical - Stryker For more information visit http://www.researchandmarkets.com/research/hs...h_american
MDT: 78.01 (+0.93), STJ: 73.55 (+4.43)
St. Jude, Abbott Labs Beat Q1 Expectations
at Investor's Business Daily - Wed Apr 22, 9:54AM CDT
Two medical-product giants were rising in the stock market early Wednesday after beating first-quarter expectations. St. Jude Medical (STJ) jumped 6.5% to a new high above 73 after it reported earnings of 91 cents a share, up 6% from the year-earlier...
ABT: 48.35 (+1.23), STJ: 73.55 (+4.43), ABBV: 64.52 (+0.91)
St. Jude Medical (STJ) Beats on Q1 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:52AM CDT
St. Jude Medical Inc (STJ) reported adjusted earnings per share (EPS) of 93 cents in the first quarter of 2015, outpacing the Zacks Consensus Estimate by a couple of cents.
CAPR: 7.50 (+0.76), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), STJ: 73.55 (+4.43)
Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) - Forecast to 2019
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2c5p7/asian_internal) has announced the addition of the "Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019" report to their offering. The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019 Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market. In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Asia-Pacific Internal Neuromodulation/Neurostimulation Market: Macro Indicators, By Geography, 2014 ($ Bn) 4 Executive Summary 5 Market Overview 6 Internal Neurostimulation/Neuromodulation Market, By Modality 7 Internal Neurostimulation/Neuromodulation Market, By Application 8 Internal Neurostimulation/Neuromodulation Market, By Geography 9 Internal Neurostimulation/Neuromodulation Market: Competitive Landscape 10 Internal Neurostimulation/ Neuromodulation Market, By Company - Boston Scientific Corporation (U.S.) - Cerbomed Gmbh (Germany) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Inc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/c2...n_internal
BSX: 18.41 (+0.10), MDT: 78.01 (+0.93), STJ: 73.55 (+4.43), UPI: 1.22 (-0.03), CYBX: 63.59 (+0.27)
St. Jude Medical (STJ) Q1 Earnings Top Estimates; Down Y/Y - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 7:59AM CDT
St. Jude Medical (STJ) Q1 Earnings Top Estimates; Down Y/Y
STJ: 73.55 (+4.43)
St. Jude Q1 revenues off 1%; EPS up 8%; guidance updated
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:10AM CDT
STJ: 73.55 (+4.43)
St. Jude Medical beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 6:17AM CDT
STJ: 73.55 (+4.43)
St. Jude Medical Reports First Quarter 2015 Results
Business Wire - Wed Apr 22, 6:15AM CDT
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings for the first quarter ended April 4, 2015.
STJ: 73.55 (+4.43)
SmarTrend Watching for Potential Pullback in Shares of St Jude Medical After 1.30% Gain
Comtex SmarTrend(R) - Tue Apr 21, 5:38PM CDT
St Jude Medical (NYSE:STJ) traded in a range yesterday that spanned from a low of $68.20 to a high of $69.22. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $68.65 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
STJ: 73.55 (+4.43)
Watch for St Jude Medical to Potentially Pullback After Gaining 1.30% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 5:38PM CDT
St Jude Medical (NYSE:STJ) traded in a range yesterday that spanned from a low of $68.20 to a high of $69.22. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $68.65 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
STJ: 73.55 (+4.43)
Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:30PM CDT
DHI: 27.03 (-1.53), MKTX: 88.66 (-1.35), NLSN: 46.10 (+0.27), SEIC: 45.99 (+0.68), AZZ: 46.11 (-0.02), HBAN: 11.03 (-0.14), TDY: 109.69 (+0.48), PCH: 37.47 (-0.65), WERN: 30.29 (-1.11), NS: 65.49 (+1.78), BABY: 41.64 (+1.71), APH: 56.81 (-1.35), TEL: 70.14 (+0.13), R: 97.95 (+1.15), ANGI: 6.46 (+0.31), EVR: 50.80 (+1.28), CFG: 25.49 (+0.45), SIX: 49.97 (+1.37), EMC: 27.13 (+0.81), OC: 42.28 (-0.61), WAB: 98.61 (+2.84), BK: 42.43 (+1.39), KO: 41.31 (+0.53), LAD: 102.54 (+0.04), ABT: 48.35 (+1.23), TMO: 130.69 (-3.75), TROW: 82.59 (-0.21), SONS: 7.89 (+0.05), ALV: 120.22 (-3.47), GNTX: 18.26 (+0.09), BA: 151.19 (-2.14), TUP: 67.25 (-2.60), KNX: 32.62 (+0.07), STJ: 73.55 (+4.43), MCD: 97.84 (+2.97), AN: 65.83 (+0.93)
St. Jude Medical to Boost Chronic Pain Management Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:25PM CDT
St. Jude Medical, Inc. (STJ) recently announced its plans to acquire Spinal Modulation, Inc., developer of the Axium Neurostimulator System.
CAPR: 7.50 (+0.76), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), STJ: 73.55 (+4.43)
Will St. Jude Medical's (STJ) Earnings Miss the Mark in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 1:30PM CDT
St. Jude Medical Inc. (STJ) is slated to release its first-quarter 2015 earnings results on Apr 22. Last quarter, the company reported earnings in line with the Zacks Consensus Estimate
VRX: 206.93 (-3.92), STJ: 73.55 (+4.43), LH: 126.26 (+0.35), CGNX: 50.62 (+0.48)
St. Jude to acquire Spinal Modulation
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 12:07PM CDT
STJ: 73.55 (+4.43)
St. Jude Medical Announces Intent to Acquire Spinal Modulation, Inc.
Business Wire - Mon Apr 20, 8:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it has exercised the company's exclusive option to acquire Spinal Modulation, Inc., developer of the Axium(TM) Neurostimulator System. Following the completion of this acquisition, St. Jude Medical will become the only medical device manufacturer to offer radiofrequency ablation (RFA), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation therapy solutions for the treatment of chronic pain.
STJ: 73.55 (+4.43)
St. Jude Medical's Q1 mixed
at Investor's Business Daily - 1 hr 27 mins ago
The maker of medical products reported EPS of 91 cents, up 6% from the year-earlier quarter and in line with analysts' consensus. Revenue fell 1% to $1.345 bil, but that was slightly above views. St. Jude Medical (STJ) forecast Q2 EPS toward the high...
STJ: 73.55 (+4.43)
St. Jude Medical's (STJ) CEO Daniel J. Starks on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 22, 2:15PM CDT
STJ: 73.55 (+4.43)
St. Jude Medical (STJ) Hits 52-Week High on Earnings Beat
at The Street - Wed Apr 22, 1:14PM CDT
Shares of St. Jude Medical (STJ) hit a one-year high of $73.74 on Wednesday after the medical technology developer reported first-quarter earnings that edged analysts' expectations.
STJ: 73.55 (+4.43)
ST JUDE MEDICAL INC (STJ) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Wed Apr 22, 1:08PM CDT
The following ST JUDE MEDICAL INC (STJ) conference call took place on April 22, 2015, 08:00 AM ET. This is a transcript of that earnings call:
STJ: 73.55 (+4.43)
Jim Cramer Sees St. Jude Medical 'Leapfrogging' Competition
at The Street - Wed Apr 22, 10:42AM CDT
TheStreet's Jim Cramer says shares of St. Jude Medical are not done going higher.
STJ: 73.55 (+4.43), XLV: 74.35 (+0.12)
North American Nerve Repair & Regeneration Market by Type, by Procedure - Forecast to 2019
M2 - Wed Apr 22, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs9468/north_american) has announced the addition of the "North American Nerve Repair & Regeneration Market by Type (Neurostimulation, Nerve Conduits, Nerve Protectors, Nerve Wraps, Nerve Connectors), by Procedure (Direct Nerve Repair, Nerve Grafting, Neuromodulation Surgery, Stem Cell Therapy) -Forecast to 2019" report to their offering. The North American nerve repair and regeneration market was valued at $1,671.4 million in 2014. It is projected to reach $2,873.0 million by 2019, at a CAGR of 11.4% during the forecast period. The market, by type, is segmented into nerve repair by neurostimulation (held largest share in 2014) and nerve repair by biomaterials. In North America, the U.S. is a key region the for nerve repair and regeneration market. Nerve repair and regeneration deals with healing damaged nerves and restoring any functioning of body parts lost due to nerve damage. This is one of the more challenging of neurological procedures. The growth of nerve repair and regeneration market has been rapid in all countries, mainly due to the constantly rising surgeries pertaining to nerves and the high incidence of chronic neurological disorders like epilepsy, Parkinson's, and Alzheimer's diseases. The increase in neurological surgeries drives the need for products such as nerve conduits, wraps, protectors, and connectors; thus, it is a driver of market growth. The North American nerve repair and regeneration market constitutes 32.8% of the global nerve repair and regeneration. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Nerve Repair and Regeneration Market, By Product 6 Nerve Repair and Regeneration Market, By Country 7 Nerve Repair and Regeneration Market: Competitive Landscape 8 Nerve Repair and Regeneration Market: Company Profiles - Axogen, Inc. - Integra Lifesciences Corporation - Medtronic, Plc. - Polyganics - St. Jude Medical - Stryker For more information visit http://www.researchandmarkets.com/research/hs...h_american
MDT: 78.01 (+0.93), STJ: 73.55 (+4.43)
St. Jude, Abbott Labs Beat Q1 Expectations
at Investor's Business Daily - Wed Apr 22, 9:54AM CDT
Two medical-product giants were rising in the stock market early Wednesday after beating first-quarter expectations. St. Jude Medical (STJ) jumped 6.5% to a new high above 73 after it reported earnings of 91 cents a share, up 6% from the year-earlier...
ABT: 48.35 (+1.23), STJ: 73.55 (+4.43), ABBV: 64.52 (+0.91)
St. Jude Medical (STJ) Beats on Q1 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:52AM CDT
St. Jude Medical Inc (STJ) reported adjusted earnings per share (EPS) of 93 cents in the first quarter of 2015, outpacing the Zacks Consensus Estimate by a couple of cents.
CAPR: 7.50 (+0.76), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), STJ: 73.55 (+4.43)
Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) - Forecast to 2019
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2c5p7/asian_internal) has announced the addition of the "Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019" report to their offering. The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019 Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market. In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Asia-Pacific Internal Neuromodulation/Neurostimulation Market: Macro Indicators, By Geography, 2014 ($ Bn) 4 Executive Summary 5 Market Overview 6 Internal Neurostimulation/Neuromodulation Market, By Modality 7 Internal Neurostimulation/Neuromodulation Market, By Application 8 Internal Neurostimulation/Neuromodulation Market, By Geography 9 Internal Neurostimulation/Neuromodulation Market: Competitive Landscape 10 Internal Neurostimulation/ Neuromodulation Market, By Company - Boston Scientific Corporation (U.S.) - Cerbomed Gmbh (Germany) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Inc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/c2...n_internal
BSX: 18.41 (+0.10), MDT: 78.01 (+0.93), STJ: 73.55 (+4.43), UPI: 1.22 (-0.03), CYBX: 63.59 (+0.27)
St. Jude Medical (STJ) Q1 Earnings Top Estimates; Down Y/Y - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 7:59AM CDT
St. Jude Medical (STJ) Q1 Earnings Top Estimates; Down Y/Y
STJ: 73.55 (+4.43)
St. Jude Q1 revenues off 1%; EPS up 8%; guidance updated
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:10AM CDT
STJ: 73.55 (+4.43)
St. Jude Medical beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 6:17AM CDT
STJ: 73.55 (+4.43)
St. Jude Medical Reports First Quarter 2015 Results
Business Wire - Wed Apr 22, 6:15AM CDT
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings for the first quarter ended April 4, 2015.
STJ: 73.55 (+4.43)
SmarTrend Watching for Potential Pullback in Shares of St Jude Medical After 1.30% Gain
Comtex SmarTrend(R) - Tue Apr 21, 5:38PM CDT
St Jude Medical (NYSE:STJ) traded in a range yesterday that spanned from a low of $68.20 to a high of $69.22. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $68.65 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
STJ: 73.55 (+4.43)
Watch for St Jude Medical to Potentially Pullback After Gaining 1.30% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 5:38PM CDT
St Jude Medical (NYSE:STJ) traded in a range yesterday that spanned from a low of $68.20 to a high of $69.22. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $68.65 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
STJ: 73.55 (+4.43)
Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:30PM CDT
DHI: 27.03 (-1.53), MKTX: 88.66 (-1.35), NLSN: 46.10 (+0.27), SEIC: 45.99 (+0.68), AZZ: 46.11 (-0.02), HBAN: 11.03 (-0.14), TDY: 109.69 (+0.48), PCH: 37.47 (-0.65), WERN: 30.29 (-1.11), NS: 65.49 (+1.78), BABY: 41.64 (+1.71), APH: 56.81 (-1.35), TEL: 70.14 (+0.13), R: 97.95 (+1.15), ANGI: 6.46 (+0.31), EVR: 50.80 (+1.28), CFG: 25.49 (+0.45), SIX: 49.97 (+1.37), EMC: 27.13 (+0.81), OC: 42.28 (-0.61), WAB: 98.61 (+2.84), BK: 42.43 (+1.39), KO: 41.31 (+0.53), LAD: 102.54 (+0.04), ABT: 48.35 (+1.23), TMO: 130.69 (-3.75), TROW: 82.59 (-0.21), SONS: 7.89 (+0.05), ALV: 120.22 (-3.47), GNTX: 18.26 (+0.09), BA: 151.19 (-2.14), TUP: 67.25 (-2.60), KNX: 32.62 (+0.07), STJ: 73.55 (+4.43), MCD: 97.84 (+2.97), AN: 65.83 (+0.93)
St. Jude Medical to Boost Chronic Pain Management Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:25PM CDT
St. Jude Medical, Inc. (STJ) recently announced its plans to acquire Spinal Modulation, Inc., developer of the Axium Neurostimulator System.
CAPR: 7.50 (+0.76), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), STJ: 73.55 (+4.43)
Will St. Jude Medical's (STJ) Earnings Miss the Mark in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 1:30PM CDT
St. Jude Medical Inc. (STJ) is slated to release its first-quarter 2015 earnings results on Apr 22. Last quarter, the company reported earnings in line with the Zacks Consensus Estimate
VRX: 206.93 (-3.92), STJ: 73.55 (+4.43), LH: 126.26 (+0.35), CGNX: 50.62 (+0.48)
St. Jude to acquire Spinal Modulation
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 12:07PM CDT
STJ: 73.55 (+4.43)
St. Jude Medical Announces Intent to Acquire Spinal Modulation, Inc.
Business Wire - Mon Apr 20, 8:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it has exercised the company's exclusive option to acquire Spinal Modulation, Inc., developer of the Axium(TM) Neurostimulator System. Following the completion of this acquisition, St. Jude Medical will become the only medical device manufacturer to offer radiofrequency ablation (RFA), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation therapy solutions for the treatment of chronic pain.
STJ: 73.55 (+4.43)
